Paul D. Nathan

Learn More
BACKGROUND Response assessment is critical in evaluating effectiveness of anticancer treatment. Tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) are associated with significant(More)
3015 Background: BIBF 1120 is a potent inhibitor of VEGFR, PDGFR, FGFR kinases, and of members of the Src family of tyrosine kinases (Src, Lck, Lyn). METHODS Patients (Pts) with advanced solid(More)
Uveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway activation. Treatment with selumetinib (AZD6244, ARRY-142886), a MEK1/2 inhibitor, results in(More)